Beta Bionics (Nasdaq:BBNX) announced today that it went public after pricing a significantly upsized initial public offering ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).

A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced that it entered into a new partnership with Life Time Inc., an operator of athletic ...

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO). Earlier this month, the maker of the iLet bionic pancreas filed a registration ...

The MiniMed 780G with the Simplera Sync CGM and accompanying devices. [Image courtesy of Medtronic] The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline ...

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet] Insulet (Nasdaq:PODD) announced today that it launched the Omnipod 5 system in five more European countries. The company now offers the ...

Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. BTIG’s Marie Thibault, Sam Eiber and ...